Hikma Pharmaceuticals PLC Annual Report 2014 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS continued 4.
SEGMENTAL REPORTING For management purposes, the Group is currently organised into three principal operating divisions: Branded, Injectables and Generics.
These divisions are the basis on which the Group reports its segmental information.
The Group discloses underlying operating profit as the measure of segmental result, as this is the measure used in the decision-making andresource allocation process of the chief operating decision maker, who is the Groups Chief Executive Officer.
Information regarding the Groups operating segments is reported below.
The following is an analysis of the Groups revenue and results by reportable segment in 2014: Branded Injectables Generics Others Group Year ended 31 December 2014 $m $m $m $m $m Revenue 551 713 216 9 1,489 Cost of sales 284 282 66 6 638 Gross profit 267 431 150 3 851 Adjusted segment result 111 265 113 5 484 Exceptional items: Intangible amortisation 9 5 14 Segment result 102 260 113 5 470 Adjusted unallocated corporate expenses 57 Exceptional items: Acquisition-related expenses 11 Unallocated corporate expenses 68 Adjusted operating profit 427 Operating profit 402 Associated companies Share of results 6 Finance income 4 Finance expense 38 Profit before tax 362 Tax 80 Profit for the year 282 Attributable to: Non-controlling interest 4 Equity holders of the parent 278 282 Segment result is defined as operating profit for each segment.
Intangible amortisation comprises the amortisation on intangible assets other than software Others mainly comprises Arab Medical Containers Ltd, International Pharmaceutical Research Center Ltd and the chemicals division  Ltd Jordan.
Unallocated corporate expenses are primarily made up of employee costs, professional fees, travel expenses and donations.
SEGMENTAL REPORTING CONTINUED Corporate Branded Injectables Generics and Others Group Segment assets and liabilities 2014 $m $m $m $m $m Additions to property, plant and equipment cost 48 31 8 2 89 Acquisition of subsidiaries property, plant and equipment net book value 53 53 Additions to intangible assets 4 16 4 1 25 Intangible assets arising on acquisition 174 174 Total property, plant and equipment and intangible assets net book value 511 528 70 7 1,116 Depreciation and impairment 22 18 7 2 49 Amortisation and impairment including software 10 13 23 Investment in associates and joint ventures 16 16 Balance sheet Total assets 1,123 770 175 183 2,251 Total liabilities 481 405 92 57 1,035 The following is an analysis of the Groups revenue and results by reportable segment in 2013: Branded Injectables Generics Others Group Year ended 31 December 2013 $m $m $m $m $m Revenue 554 536 268 7 1,365 Cost of sales 278 254 62 7 601 Gross profit 276 282 206 764 Adjusted segment result 135 166 166 9 458 Exceptional items: Severance costs 1 1 Plant remediation costs 24 24 Impairment losses 6 4 10 Other claims provisions 11 11 Intangible amortisation 10 5 15 Segment result 124 155 127 9 397 Unallocated corporate expenses 45 Adjusted operating profit 413 Operating profit 352 Associated companies Share of results 3 Exceptional impairment of investment 16 Finance income 2 Finance expense 37 Profit before tax 298 Tax 82 Profit for the year 216 Attributable to: Non-controlling interest 4 Equity holders of the parent 212 216 Segment result is defined as operating profit for each segment.
Intangible amortisation comprises the amortisation of intangible assets other than software Others mainly comprise Arab Medical Containers Ltd, International Pharmaceutical Research Center Ltd and the chemicals division  Ltd Jordan.
Unallocated corporate expenses are primarily made up of employee costs, office costs, professional fees, donations and travel expenses.
137 Hikma Pharmaceuticals PLC Annual Report 2014 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS continued 4.
SEGMENTAL REPORTING CONTINUED Corporate and Branded Injectables Generics Others Group Segment assets and liabilities 2013 $m $m $m $m $m Additions to property, plant and equipment cost 25 31 10 66 Acquisition of subsidiaries property, plant and equipment net book value 6 6 Additions to intangible assets 3 13 2 18 Intangible assets arising on acquisition 20 20 Total property, plant and equipment and intangible assets net book value 519 314 51 6 890 Depreciation and impairment 22 17 8 2 49 Amortisation and impairment including software 10 12 4 26 Investment in associates and joint ventures 22 22 Balance sheet Total assets 1,138 592 141 58 1,929 Total liabilities 551 259 25 60 895 The following table provides an analysis of the Groups sales by geographical market, irrespective of the origin of the goods services: 2014 2013 $m $m Middle East and North Africa 633 638 US 763 631 Europe and Rest of the World 89 89 UK 4 7 1,489 1,365 The top-selling markets were as below: 2014 2013 $m $m US 763 631 Saudi Arabia 146 132 Algeria 86 125 995 888 Generics and Injectables revenue were $216 million and $713 million, respectively 2013: $268 million and $536 million including strong sales of doxycycline and glycopyrrolate.
Included in revenues arising from the Generics and Injectables segments are revenues of approximately $221 million 2013: $172 million which arose from the Groups largest customer which is located in the US.
The following is an analysis of the total non-current assets excluding deferred tax and financial instruments and an analysis of total assets bythe geographical area in which the assets are located: Total non-current assets excluding deferred tax and financial instruments as at 31 December Total assets as at 31 December 2014 2013 2014 2013 $m $m $m $m Middle East and North Africa 606 624 1,202 1,255 Europe 141 156 195 217 US 368 163 648 437 UK 55 3 206 20 1,170 946 2,251 1,929 138
